Showing results (71-80 of 588) with videos related to
Sort By:
Pageof 59
Cancers|November 27, 2025
KIT-Mutant Melanoma: Understanding the Pathway to Personalized TherapyAditi Kaveti, Ryan J Sullivan, Hensin TsaoJournal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRichard W Joseph, Ryan J Sullivan, Robyn Harrell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanomaDavid J Panka, Michael B Atkins, James W MierThe Oncologist|March 1, 2018
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive ReviewNizar M Tannir, Sumanta K Pal, Michael B AtkinsJournal of Translational Medicine|July 5, 2015
What's new in melanoma? Combination!Paolo A Ascierto, Francesco M Marincola, Michael B AtkinsCancers|February 15, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?Eric Jonasch, Michael B Atkins, Simon Chowdhury, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
New options and new questions: how to select and sequence therapies for patients with metastatic melanomaKeith T Flaherty, Jeff A Sosman, Michael B AtkinsJournal for Immunotherapy of Cancer|May 22, 2020
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapyMichael T Serzan, Princy N Kumar, Michael B AtkinsThe Lancet. Oncology|December 8, 2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapyGeoffrey T Gibney, Louis M Weiner, Michael B AtkinsClinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B AtkinsPageof 59